Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)
Completed · Phase 1
Conditions studied: Type 2 Diabetes Mellitus
In brief
It is anticipated that 7 days of oral administration of 10 mg dapagliflozin will reduce the renal glucose reabsorption similarly in healthy subjects and in subjects with T2DM.
Key facts
- Study ID
- NCT01165268
- Run by
- AstraZeneca
- People needed
- 24
- Starts
- 2010-08-01
- Expected to finish
- 2010-12-01
- Last updated by the study team
- 2016-11-17
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Profil Institute For Clinical Research, Inc. — Chula Vista, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.